News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
865,147 Results
Type
Article (87641)
Company Profile (824)
Press Release (776666)
Multimedia
Podcasts (182)
Webinars (28)
Section
Business (233146)
Career Advice (4142)
Deals (39825)
Drug Delivery (141)
Drug Development (91317)
Employer Resources (203)
FDA (18319)
Job Trends (17412)
News (397596)
Policy (39935)
Tag
Academia (3006)
Academic (2)
Accelerated approval (21)
Adcomms (35)
Allergies (134)
Alliances (56980)
ALS (155)
Alzheimer's disease (1721)
Antibody-drug conjugate (ADC) (283)
Approvals (18387)
Artificial intelligence (554)
Autoimmune disease (121)
Automation (32)
Bankruptcy (406)
Best Places to Work (12634)
BIOSECURE Act (23)
Biosimilars (177)
Biotechnology (487)
Bladder cancer (143)
Brain cancer (56)
Breast cancer (546)
Cancer (4390)
Cardiovascular disease (390)
Career advice (3563)
Career pathing (39)
CAR-T (264)
CDC (57)
Cell therapy (731)
Cervical cancer (34)
Clinical research (76140)
Collaboration (1518)
Company closure (4)
Compensation (1008)
Complete response letters (64)
COVID-19 (2968)
CRISPR (92)
C-suite (679)
Cystic fibrosis (144)
Data (5330)
Decentralized trials (2)
Denatured (66)
Depression (125)
Diabetes (480)
Diagnostics (7134)
Digital health (41)
Diversity (12)
Diversity, equity & inclusion (49)
Drug discovery (258)
Drug pricing (201)
Drug shortages (36)
Duchenne muscular dystrophy (215)
Earnings (99831)
Editorial (57)
Employer branding (25)
Employer resources (173)
Events (134019)
Executive appointments (1004)
FDA (21024)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (21)
Funding (1366)
Gene editing (197)
Generative AI (54)
Gene therapy (595)
GLP-1 (1061)
Government (5404)
Grass and pollen (8)
Guidances (377)
Healthcare (20941)
HIV (54)
Huntington's disease (43)
IgA nephropathy (76)
Immunology and inflammation (268)
Immuno-oncology (27)
Indications (65)
Infectious disease (3231)
Inflammatory bowel disease (196)
Inflation Reduction Act (16)
Influenza (107)
Intellectual property (207)
Interviews (816)
IPO (17937)
IRA (59)
Job creations (5198)
Job search strategy (2866)
Kidney cancer (17)
Labor market (87)
Layoffs (651)
Leadership (37)
Legal (10153)
Liver cancer (94)
Longevity (14)
Lung cancer (625)
Lymphoma (306)
Machine learning (35)
Management (66)
Manufacturing (705)
MASH (163)
Medical device (14945)
Medtech (14982)
Mergers & acquisitions (22837)
Metabolic disorders (1251)
Multiple sclerosis (147)
NASH (23)
Neurodegenerative disease (271)
Neuropsychiatric disorders (78)
Neuroscience (2863)
NextGen: Class of 2025 (7703)
Non-profit (5098)
Now hiring (60)
Obesity (596)
Opinion (321)
Ovarian cancer (149)
Pain (176)
Pancreatic cancer (189)
Parkinson's disease (257)
Partnered (32)
Patents (446)
Patient recruitment (363)
Peanut (58)
People (66495)
Pharmaceutical (145)
Pharmacy benefit managers (29)
Phase I (23490)
Phase II (33043)
Phase III (24910)
Pipeline (3472)
Policy (312)
Postmarket research (3554)
Preclinical (10618)
Press Release (72)
Prostate cancer (218)
Psychedelics (52)
Radiopharmaceuticals (284)
Rare diseases (734)
Real estate (7431)
Recruiting (80)
Regulatory (28313)
Reports (65)
Research institute (2709)
Resumes & cover letters (651)
Rett syndrome (21)
RNA editing (16)
RSV (81)
Schizophrenia (144)
Series A (222)
Series B (168)
Service/supplier (30)
Sickle cell disease (87)
Special edition (26)
Spinal muscular atrophy (171)
Sponsored (42)
Startups (4322)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (96)
The Weekly (114)
Vaccines (1079)
Venture capital (74)
Weight loss (417)
Women's health (69)
Worklife (21)
Date
Today (94)
Last 7 days (662)
Last 30 days (3677)
Last 365 days (33419)
2025 (30683)
2024 (38142)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1288)
Alabama (83)
Alaska (7)
Arizona (316)
Arkansas (14)
Asia (51165)
Australia (8999)
California (10432)
Canada (3062)
China (988)
Colorado (440)
Connecticut (472)
Delaware (301)
Europe (117701)
Florida (1527)
Georgia (340)
Hawaii (3)
Idaho (68)
Illinois (854)
India (59)
Indiana (504)
Iowa (21)
Japan (350)
Kansas (130)
Kentucky (40)
Louisiana (28)
Maine (81)
Maryland (1371)
Massachusetts (7754)
Michigan (331)
Minnesota (608)
Mississippi (6)
Missouri (129)
Montana (34)
Nebraska (27)
Nevada (112)
New Hampshire (81)
New Jersey (2860)
New Mexico (32)
New York (2796)
North Carolina (1499)
North Dakota (10)
Northern California (4870)
Ohio (319)
Oklahoma (22)
Oregon (51)
Pennsylvania (2136)
Puerto Rico (20)
Rhode Island (47)
South America (1656)
South Carolina (57)
South Dakota (1)
Southern California (3996)
Tennessee (161)
Texas (1632)
United States (38075)
Utah (313)
Vermont (1)
Virginia (265)
Washington D.C. (85)
Washington State (875)
West Virginia (4)
Wisconsin (107)
Wyoming (2)
There are 865,147 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s disease
J&J’s Anti-Tau Bet Falls Flat in Mid-Stage Alzheimer’s Trial
Johnson & Johnson will discontinue the Phase II Auτonomy study of posdinemab after a scheduled review found the anti-tau antibody failed to slow clinical decline in patients with early Alzheimer’s disease.
November 24, 2025
·
1 min read
·
Heather McKenzie
Alzheimer’s disease
Biogen’s Leqembi Rises After Novo GLP-1 Fails in Alzheimer’s
Analysts agree that the failure of Novo Nordisk’s semaglutide to reduce Alzheimer’s disease progression removes a “modest” or “perceived” overhang on Biogen and the anti-amyloid antibody class in general, clearing the way for increased uptake of Leqembi and Eli Lilly’s Kisunla.
November 24, 2025
·
3 min read
·
Heather McKenzie
Press Releases
Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership
November 24, 2025
·
3 min read
Press Releases
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
November 24, 2025
·
4 min read
Press Releases
Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1
November 24, 2025
·
4 min read
Press Releases
Vertero Initiates Phase 1 Study of VT-5006, A Selective Small Molecule Therapy for Parkinson’s Disease
November 24, 2025
·
3 min read
Press Releases
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates
November 24, 2025
·
18 min read
Press Releases
Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases
November 24, 2025
·
6 min read
Press Releases
Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting
November 24, 2025
·
3 min read
Press Releases
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
November 24, 2025
·
8 min read
1 of 86,515
Next
